428
Views
15
CrossRef citations to date
0
Altmetric
Short Communication

Expression of ER stress markers (GRP78/BiP and PERK) in adenoid cystic carcinoma

, , , , , , , & show all
Pages 1-7 | Received 30 Apr 2015, Accepted 31 Jul 2015, Published online: 14 Sep 2015
 

Abstract

Conclusion: A high GRP78/BiP expression was proved to be a significant marker for predicting poor outcome after surgery. GRP78/BiP may be a promising molecular target for treatment of ACC. Background: The glucose-regulated protein GRP78/BiP plays a crucial role in the endoplasmic reticulum (ER) stress. The level of GRP78 is highly elevated in various human cancers, but the clinicopathological significance of GRP78/BiP remains controversial in patients with adenoid cystic carcinoma (ACC). Methods: A total of 26 ACC patients were analyzed, and tumor specimens were stained by immunohistochemistry for GRP78/BiP, PERK, Ki-67, and microvessel density (MVD) determined by CD34. Results: GRP78/BiP and PERK were highly expressed in 58% (15/26) and 35% (9/26), respectively. The high expression of GRP78/BiP was significantly associated with PERK, cell proliferation and angiogenesis.

Acknowledgements

We thank Ms Yuka Matsui for her technical assistance of manuscript submission. We also deeply appreciate Professor Masahiko Nishiyama of the Department of Molecular Pharmacology and Oncology, Gunma University Graduate School of Medicine, for the critical review of this manuscript.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Supplementary material available online

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.